BioGaia ABBGLAF 100 Interest Coverage is 50.73 as of Mar. 2026, which is 86% below its 10-year median of 356.45. GuruFocus rates BGLAF with a GF Score™ of 100/100 and a GF Value™ of $13.05. The stock has 5 warning signs investors should review. Among 685 Drug Manufacturers companies, BioGaia AB ranks better than 70.8% on this metric.
Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's
Operating Income
by its Interest Expense. BioGaia AB's
Operating Income
for the
three
months ended in Mar. 2026 was $10.9 Mil. BioGaia AB's Interest Expense for the
three
months ended in Mar. 2026 was $-0.2 Mil.
BioGaia AB's interest coverage for the quarter that ended in Mar. 2026 was 50.73.
The higher the ratio, the stronger the company's financial strength is.
The historical rank and industry rank for BioGaia AB's Interest Coverage or its related term are showing as below:
BGLAF'
s Interest Coverage Range Over the Past 10 Years
Min: 49.97 Med: 356.45 Max: 1598.45
Current: 49.97
BGLAF's Interest Coverage is ranked better than 70.8% of 685
companies
in the Drug Manufacturers industry
Industry Median: 12.78
vs BGLAF: 49.97
BioGaia AB (OTCPK:BGLAF) Interest Coverage Explanation
Ben Graham requires that a company has a minimum interest coverage of 5 with the companies he invested. If the interest coverage is less than 2, the company is burdened by debt. Any business slow or recession may drag the company into a situation where it cannot pay the interest on its debt.
Interest Coverage is an important factor when GuruFocus ranks a company's overage Financial Strength .
BioGaia AB Interest Coverage Related Terms
BioGaia AB Interest Coverage Historical Data
* Premium members only.
The historical data trend for BioGaia AB's Interest Coverage can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Note: For Interest Coverage, "No debt" indicates no long-term debt. An indication of "No Debt" does not necessarily mean that the company has no long-term debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.
For the Drug Manufacturers - Specialty & Generic subindustry, BioGaia AB's Interest Coverage, along with its competitors' market caps and Interest Coverage data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
BioGaia AB Interest Coverage vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, BioGaia AB's Interest Coverage distribution charts can be found below:
* The bar in red indicates where BioGaia AB's Interest Coverage falls into.
Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income (EBIT) by its Interest Expense:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
BioGaia AB (BGLAF) has a Interest Coverage of 50.73 as of Mar. 2026. Interest Coverage measures a company's capability to pay interest expenses on its debt. View historical data on BioGaia AB and its competitors. This is 86% below median its historical median of 356.45. Over the past decade, BioGaia AB's Interest Coverage has ranged from 49.97 to 1,598.45. According to the industry distribution chart, BioGaia AB ranks #200 out of 685 companies in the Drug Manufacturers industry, placing it in the top 29.2%.
Is BioGaia AB's Interest Coverage too high?
BioGaia AB's current Interest Coverage of 50.73 is 86% below median its 10-year median of 356.45. Over the past 10 years, this metric has ranged from a low of 49.97 to a high of 1,598.45. The Drug Manufacturers industry median Interest Coverage is 12.78. BioGaia AB's value of 50.73 is 296.9% above this industry median. Based on the distribution chart, BioGaia AB ranks #200 out of 685 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, BioGaia AB has a GF Score™ of 100/100, reflecting its overall financial health beyond just this single metric.
How does BioGaia AB's Interest Coverage compare to ZTS?
According to the Drug Manufacturers industry distribution chart, BioGaia AB ranks #200 out of 685 companies for Interest Coverage. This puts BioGaia AB in the upper half of its industry. The industry median Interest Coverage is 12.78. BioGaia AB's value of 50.73 is 296.9% above this benchmark. Historically, BioGaia AB's own Interest Coverage has ranged from 49.97 to 1,598.45 over the past decade. While the company's 10-year median is 356.45 vs. the industry median of 12.78, BioGaia AB has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Interest Coverage for a Drug Manufacturers company?
The median Interest Coverage among Drug Manufacturers companies is 12.78, based on 685 companies in the industry. Companies in the top quartile (top 25%) have a Interest Coverage significantly above this median, while those in the bottom quartile fall well below. However, Interest Coverage should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. BioGaia AB's current Interest Coverage of 50.73 is 296.9% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Interest Coverage mean?
A high Interest Coverage can signal that a stock is expensive relative to its fundamentals. Interest Coverage measures a company's capability to pay interest expenses on its debt. View historical data on BioGaia AB and its competitors. For the Drug Manufacturers industry, the median Interest Coverage is 12.78 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. BioGaia AB's current Interest Coverage is 50.73, which is 86% below median its own 10-year median of 356.45. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is BioGaia AB stock overvalued right now?
BioGaia AB (BGLAF) has a current Interest Coverage of 50.73. The stock's GF Value™ is $13.05, compared to a current price of $12.20 — trading 6.5% below its estimated fair value. The current Interest Coverage is 50.73, which is 86% below median its 10-year median of 356.45 and 296.9% above the Drug Manufacturers industry median of 12.78. BioGaia AB's overall GF Score™ is 100/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Interest Coverage calculated?
Interest Coverage is calculated from a company's financial statements. For BioGaia AB (BGLAF), the current Interest Coverage is 50.73 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is BioGaia AB (BGLAF) Overvalued in 2026?
Based on GuruFocus' analysis, BioGaia AB stock appears to be undervalued.
The current stock price of $12.20 is trading 6.5% below its estimated GF Value™ of $13.05.
Key valuation signals for BGLAF:
Interest Coverage: 50.73 (86% below median its 10-year median of 356.45)
GF Value™: $13.05 vs. price of $12.20 (6.5% below fair value)
Industry Position: 296.9% above the Drug Manufacturers median (#200 of 685)
No single metric tells the full story. See the BGLAF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
BioGaia AB is a healthcare company engaged in developing, marketing, and selling probiotic products. The company has three operating segments; Paediatrics segment includes drops, gut health tablets, oral rehydration solution (ORS) and cultures to be used as ingredients in licensee products such as infant formula, as well as royalty revenue for pediatric products, Adult Health segment includes gut health tablets, oral health lozenges and cultures as an ingredient in a licensee's dairy products, and Other segment include royalties in respect of development projects, revenue from packaging solutions in the subsidiary CapAble, etc. Geographically, it operates in three regions: EMEA, the Americas, and APAC (Asia-Pacific, Australia, and New Zealand).
100GF Score
Get the complete analysis for BGLAF
Interest Coverage is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BGLAF has been successfully added to your 
